Q4 2022 Earnings Estimate for Harmony Biosciences Holdings, Inc. Issued By Oppenheimer (NASDAQ:HRMY)

Posted by MarketBeat News on Aug 5th, 2022

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) – Analysts at Oppenheimer dropped their Q4 2022 earnings estimates for Harmony Biosciences in a report released on Tuesday, August 2nd. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of $0.43 per share for the quarter, down from their previous forecast of $0.52. Oppenheimer currently has a “Outperform” rating and a $67.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $1.69 per share. Oppenheimer also issued estimates for Harmony Biosciences’ Q1 2023 earnings at $0.41 EPS, Q2 2023 earnings at $0.56 EPS, Q3 2023 earnings at $0.60 EPS and Q4 2023 earnings at $0.66 EPS.

Harmony Biosciences (NASDAQ:HRMY – Get Rating) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.05). Harmony Biosciences had a net margin of 15.95% and a return on equity of 60.12%. During the same quarter in the previous year, the firm posted $0.54 EPS.

Several other research firms have also commented on HRMY. Cantor Fitzgerald began coverage on shares of Harmony Biosciences in a research note on Thursday, April 14th. They set an “overweight” rating and a $63.00 price objective on the stock. Raymond James boosted their price objective on shares of Harmony Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday. Jefferies Financial Group lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $57.00 price objective on the stock. in a research note on Wednesday. The Goldman Sachs Group lowered shares of Harmony Biosciences from a “buy” rating to a “neutral” rating and set a $55.00 price objective on the stock. in a research note on Tuesday, July 12th. Finally, Mizuho dropped their price objective on shares of Harmony Biosciences from $64.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $59.86.

Harmony Biosciences Trading Up 0.1 %

NASDAQ:HRMY opened at $52.36 on Thursday. Harmony Biosciences has a one year low of $26.06 and a one year high of $57.13. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.91 and a quick ratio of 4.88. The company’s 50-day simple moving average is $49.37 and its 200 day simple moving average is $44.94. The firm has a market capitalization of $3.09 billion, a P/E ratio of 55.12 and a beta of 0.33.

Insider Transactions at Harmony Biosciences

In other news, CEO John C. Jacobs sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $44.18, for a total value of $1,104,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Jack Nielsen sold 86,209 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $52.37, for a total transaction of $4,514,765.33. Following the transaction, the director now owns 3,750,044 shares in the company, valued at $196,389,804.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO John C. Jacobs sold 25,000 shares of the stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $44.18, for a total transaction of $1,104,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 489,667 shares of company stock worth $26,332,662. Corporate insiders own 34.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Catalyst Capital Advisors LLC bought a new position in Harmony Biosciences during the first quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new position in Harmony Biosciences during the first quarter valued at approximately $74,000. Acadian Asset Management LLC purchased a new stake in Harmony Biosciences during the fourth quarter valued at approximately $84,000. KBC Group NV purchased a new stake in Harmony Biosciences during the second quarter valued at approximately $98,000. Finally, Mutual of America Capital Management LLC purchased a new stake in Harmony Biosciences during the fourth quarter valued at approximately $133,000. Institutional investors own 75.62% of the company’s stock.

Harmony Biosciences Company Profile

(Get Rating)

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.